OncoC4 Inc. has reported preliminary Phase 1/2 results for investigational PD-1/VEGF bispecific antibody cesalatamig, or AI-081, in patients with PD-(L)1-resistant or refractory non-small cell lung cancer, with the company identifying 10 mg/kg every three weeks as the dose for further development. Among 21 efficacy-evaluable patients treated at that dose, the investigator-assessed objective response rate was 33% and the disease control rate was 90%, according to pooled data from the global BiPAVE-001 and Chinese BiPAVE-001 CN studies presented at the Society for Immunotherapy of Cancer 2026 annual meeting.
The numbers give OncoC4 a reason to move cesalatamig towards a planned pivotal study, but they remain early evidence rather than confirmation of clinical benefit. The selected-dose efficacy cohort was small, the studies were open label and there was no randomized control arm, while the disclosed response assessment was investigator based. The programme therefore sits at an important transition point where a dose-related response signal must become reproducible evidence against a relevant comparator before cesalatamig can be judged against established post-immunotherapy treatment.
That development challenge is particularly relevant because patients whose advanced NSCLC has already progressed after platinum chemotherapy and immune checkpoint inhibition still face limited options. Current American Society of Clinical Oncology guidance recommends docetaxel with or without ramucirumab after prior chemotherapy and immunotherapy, with several other treatments available for selected patients depending on histology and molecular characteristics.
What does the 33% response rate at 10 mg/kg actually tell us about cesalatamig?
OncoC4 evaluated cesalatamig at 1, 3, 10 and 20 mg/kg every three weeks across a 103-patient NSCLC safety population. The efficacy analysis disclosed by the company included 55 patients with PD-(L)1-resistant or refractory disease, with response rates increasing from 10% at 1 mg/kg to 21% at 3 mg/kg and 33% at 10 mg/kg. Disease control rates rose in parallel from 40% to 67% and then 90%, providing the exposure-response pattern that supported selection of 10 mg/kg for further development.
The signal is clinically interesting because the patients were not treatment naive. The median number of previous therapy lines was two, 42% had received at least three prior lines and 77% had an Eastern Cooperative Oncology Group performance status of 1 at baseline. Responses were reported across PD-L1 expression levels, suggesting the observed activity was not confined to patients with high baseline PD-L1 expression in the small dataset disclosed.
However, a 33% response rate in 21 patients represents only a small number of responders, so the apparent dose-response relationship needs confirmation in a substantially larger population. The current dataset does not establish whether the responses will remain durable, whether progression-free or overall survival will improve, or whether efficacy is consistent across histological and biomarker subgroups. Those questions matter more than the headline percentage once a programme moves from dose optimisation into pivotal testing.
Disease control also requires careful interpretation. A 90% disease control rate combines objective responses with stable disease, and stable disease can vary substantially in duration and clinical relevance. For a heavily pretreated population, prolonged stability may be valuable, but the current disclosure does not provide enough mature duration data to treat disease control as equivalent to a durable treatment benefit.
Why is PD-1 plus VEGF becoming such an important immuno-oncology strategy?
Cesalatamig is a tetravalent bispecific antibody designed to block both PD-1 and vascular endothelial growth factor within a single molecule. PD-1 blockade aims to restore antitumour T-cell activity, while VEGF inhibition can affect tumour angiogenesis and may also alter an immunosuppressive tumour microenvironment, creating a biological rationale for combining the two pathways.
OncoC4 has engineered cesalatamig with high-affinity target binding and Fc-silencing modifications intended to minimise depletion of PD-1-positive effector T cells. These design features form part of the company’s differentiation strategy, but they remain mechanistic characteristics rather than proof that cesalatamig will deliver better efficacy or tolerability than other PD-1/VEGF combinations or bispecific antibodies.
The broader interest in the pathway is already visible across lung cancer development. VEGF-directed treatment has long been used in selected NSCLC populations, while newer programmes are testing whether integrating angiogenesis inhibition more tightly with checkpoint blockade can improve outcomes. ASCO’s current guideline commentary specifically identifies VEGF-based immune combinations as an area where additional evidence is developing, underscoring that the field has not yet settled how these approaches should fit into routine care.
Cesalatamig therefore enters a scientifically attractive but increasingly competitive space. Its future value will depend less on whether PD-1 and VEGF are individually credible targets and more on whether the molecule can produce a clinically meaningful balance of response depth, durability and tolerability in patients who have already demonstrated resistance to checkpoint therapy.
Why does activity after previous immunotherapy make these data more interesting?
Re-exposing a tumour to another PD-1-directed strategy after progression on earlier PD-(L)1 therapy creates an obvious biological question. If a cancer has already escaped checkpoint inhibition, simply administering another PD-1 antibody would not necessarily be expected to reverse resistance. Cesalatamig’s development hypothesis is that simultaneous VEGF inhibition may modify the tumour environment enough to restore or enhance antitumour immune activity.
The early response signal is therefore notable because the selected population specifically had PD-(L)1-resistant or refractory disease rather than being immunotherapy naive. In September 2026, the U.S. Food and Drug Administration granted cesalatamig Fast Track designation for NSCLC progressing after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy. Fast Track status facilitates interactions with the regulator and potentially expedited development processes, but it does not constitute approval or establish that the treatment is effective.
The real test will be whether dual targeting can generate results superior to the outcomes achievable with existing subsequent-line therapy. ASCO continues to recommend docetaxel with or without ramucirumab following prior platinum chemotherapy and checkpoint inhibition, while biomarker-defined patients may have additional targeted or antibody-drug conjugate options.
Cross-trial response percentages cannot answer that question. Patient selection, prior treatment intensity, histology, biomarker composition, response assessment and follow-up can differ markedly between early cesalatamig cohorts and historical chemotherapy studies, making a randomized pivotal comparison considerably more informative than indirect percentage matching.
How much confidence can investors and clinicians place in the current safety assessment?
The pooled safety population is larger than the dose-specific efficacy cohorts, covering 103 NSCLC patients treated with cesalatamig monotherapy across 1, 3, 10 or 20 mg/kg every three weeks. Seventy-seven patients had non-squamous disease and 25 had squamous histology, and OncoC4 reported that the safety profiles were comparable between those groups and described tolerability across the studied doses as manageable.
The limitation is that the public disclosure does not provide the granular adverse-event information required for a robust safety comparison. Detailed rates of Grade 3 or higher treatment-related events, serious adverse events, treatment discontinuations, dose interruptions and adverse events of special interest were not included in the company’s November 6 announcement. That means the available evidence supports only a preliminary tolerability assessment rather than a conclusion that cesalatamig has a favourable safety profile relative to other treatments.
VEGF pathway inhibition can carry clinically important risks in oncology, including hypertension, bleeding and other vascular complications depending on the agent and treatment context, while immune checkpoint blockade has its own spectrum of immune-mediated toxicity. A pivotal programme will need to show not merely that cesalatamig can produce tumour responses, but that dual pathway inhibition remains manageable when administered for a clinically meaningful duration.
This issue may become particularly important if OncoC4 moves the drug into combinations. A therapy that is workable as monotherapy can generate a different toxicity profile when combined with chemotherapy, antibody-drug conjugates or targeted agents, so the evolving safety package will need to be evaluated separately for each regimen rather than extrapolated from the current monotherapy experience.
What does selecting 10 mg/kg mean for OncoC4’s pivotal development strategy?
Dose selection is one of the most consequential decisions in early oncology development because an unnecessarily high dose can increase toxicity without adding meaningful efficacy, while an insufficient dose can compromise a later pivotal trial. OncoC4 said exposure-response modelling and the escalating response pattern support 10 mg/kg every three weeks as the dose it plans to carry forward.
Interestingly, the safety programme included patients at 20 mg/kg, while the disclosed efficacy comparison used the 1, 3 and 10 mg/kg groups. This makes the company’s exposure-response work important because the development decision appears to be based on the balance of drug exposure and activity rather than simply advancing the highest administered dose.
BiPAVE-001 itself remains an ongoing Phase 1/2 study. The U.S. trial includes a first-in-human dose-escalation component followed by dose-optimisation work testing cesalatamig alone and with standard-of-care therapy across selected solid tumours, while the study remains listed as active.
The design of the planned pivotal study will now determine how seriously the early signal can be tested. Comparator choice, previous-treatment requirements, histology, biomarker stratification and the choice between response-based and time-to-event endpoints will all influence whether a future positive result could support a regulatory application.
Can cesalatamig differentiate itself in an increasingly crowded post-immunotherapy NSCLC market?
Treatment after chemotherapy and immune checkpoint inhibition is no longer a single undifferentiated market. Docetaxel remains an established option, frequently combined with ramucirumab, while molecular and protein-expression testing can identify patients eligible for therapies directed at HER2, MET or other alterations depending on tumour biology.
That creates both an opportunity and a challenge for cesalatamig. A biomarker-agnostic medicine capable of producing durable responses after checkpoint resistance could address patients who do not have an actionable alteration, but the bar for development rises as increasingly specific treatments divide advanced NSCLC into narrower biological groups.
OncoC4 reported responses across PD-L1 expression levels, which could support development without a PD-L1 selection requirement if the finding holds in larger studies. The current dataset is too small to conclude that PD-L1 has no predictive relevance, however, and future analyses will need to examine whether response rates, durability or survival differ across PD-L1 strata and other biological features.
Histology will also matter because the early safety dataset includes both squamous and non-squamous tumours. Anti-VEGF strategies can carry different considerations depending on tumour location, bleeding risk and histology, so a pivotal programme must demonstrate that patient selection remains appropriate across the population OncoC4 ultimately intends to pursue.
Why does OncoC4 have more riding on cesalatamig than one Phase 1/2 readout?
Cesalatamig is wholly owned by privately held OncoC4, giving the company greater economic exposure to the programme than it has to gotistobart, its separate CTLA-4 programme being co-developed with BioNTech. OncoC4 is also developing cesalatamig in combinations and additional tumour settings, including programmes involving antibody-drug conjugates and RAS-targeted therapies in China.
That makes the NSCLC monotherapy dataset an important proof-of-concept test for the wider asset. If dual PD-1/VEGF inhibition retains activity after previous checkpoint therapy and can be developed at a manageable dose, the molecule may have value both alone and as a backbone for combination regimens.
The opposite is equally relevant. If a larger controlled study produces substantially lower response rates, short response durability or problematic toxicity, the strategic assumptions supporting broader cesalatamig combinations would need to be reconsidered. Early oncology programmes often look strongest during dose expansion, before randomized evidence introduces a more demanding benchmark.
For now, the SITC data have done what a Phase 1/2 programme needs to do: they have produced a dose-selection rationale and enough antitumour activity to justify further development. They have not yet shown that cesalatamig improves progression-free survival, overall survival or patient outcomes relative to established subsequent-line treatment.
The pivotal trial now matters more than the 33% headline response rate
Cesalatamig’s 33% objective response rate and 90% disease control rate at 10 mg/kg create a credible development signal in patients whose disease has already resisted immunotherapy, particularly because activity increased across the studied efficacy doses. The small 21-patient selected-dose cohort, open-label design and investigator-assessed responses mean those figures should be treated as Phase 1/2 evidence rather than a reliable estimate of what a larger population will experience.
The current safety disclosure also leaves important information unresolved. OncoC4 has a 103-patient safety dataset and describes the treatment as manageable across doses, but granular severe toxicity, serious adverse-event and discontinuation data will be necessary before the benefit-risk profile can be compared meaningfully with established chemotherapy and anti-angiogenic options.
Selecting 10 mg/kg every three weeks therefore closes one development question while opening the much larger one. The next pivotal study must show whether coupling PD-1 and VEGF blockade within cesalatamig can turn an early response signal into durable, comparative clinical benefit after checkpoint therapy and platinum chemotherapy have failed.
